Related Experiment Videos
Toxicities of the nonsteroidal anti-inflammatory drugs
1Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Abstract:
There has been significant progress in defining the risks associated with the use of nonsteroidal anti-inflammatory drugs. There is now clear consensus that certain patient subsets are at an increased risk for gastroduodenal mucosal damage when those patients are treated with these drugs. The therapy for treating mucosal damage or preventing it has also been better defined. The studies published this year have provided a better understanding of those patients who should be considered as candidates for possible therapy for prophylaxis against mucosal damage and which drugs might be useful. The patients who are at risk to develop renal dysfunction remain less well defined. This paper reviews the current relevant literature.
Insights
Nonsteroidal anti-inflammatory drugs (NSAIDs) pose risks, particularly gastroduodenal damage in certain patients. While therapies for this damage are improving, NSAID-induced renal risks require further definition.
Area of Science:
- Gastroenterology
- Pharmacology
- Nephrology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used but associated with significant gastrointestinal risks.
- Gastroduodenal mucosal damage is a known complication, with consensus on high-risk patient subsets.
- Therapeutic strategies for preventing and treating NSAID-induced mucosal damage have advanced.
Purpose of the Study:
- To review current literature on NSAID-associated risks, focusing on gastroduodenal and renal effects.
- To identify patient populations at increased risk for NSAID-induced gastroduodenal damage.
- To evaluate the efficacy of prophylactic therapies for NSAID-induced mucosal damage.
Main Methods:
- Literature review of studies published within the relevant year.
- Analysis of consensus statements regarding NSAID risks and patient stratification.
- Synthesis of data on therapeutic interventions for mucosal protection.
Main Results:
- Clear consensus exists on identifying patients at high risk for NSAID-induced gastroduodenal damage.
- Therapeutic options for preventing and treating NSAID-induced mucosal damage are better defined.
- Identification of patients at risk for NSAID-induced renal dysfunction remains less defined.
Conclusions:
- Significant progress has been made in understanding and managing NSAID-induced gastroduodenal risks.
- Current literature better defines high-risk patients and effective prophylactic therapies for mucosal damage.
- Further research is needed to clarify risks and management of NSAID-induced renal dysfunction.